Market Forecast by Countries (Germany, United Kingdom, France, Italy, Russia, Spain, Rest of Europe), By Animal Type (Rat, Mice, Guinea Pigs, Rabbits, Others), By Application (Drug Discovery & Development, Basic Research, Others), By End Users (Pharma & Biotech Companies, Academic Research Institutes, Others) And Competitive Landscape
Product Code: ETC435925 | Publication Date: Nov 2022 | Updated Date: Oct 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 200 | No. of Figures: 90 | No. of Tables: 30 | |
According to 6Wresearch internal database and industry insights, the Europe Animal Model Market was valued at USD 1.92 billion in 2024 and is projected to reach nearly USD 3.46 billion by 2031, exhibiting a compound annual growth rate (CAGR) of 7.88% during the forecast period (2025-2031).
Report Name | Europe Animal Model Market |
Forecast period | 2025-2031 |
CAGR | 7.88% |
Market size | USD 3.46 billion by 2031 |
Growing Sector | Life Sciences & Biotechnology |
The Europe Animal Model Market report thoroughly covers the market by countries, animal types, applications, and end-users. The market report provides an unbiased and detailed analysis of ongoing market trends, opportunities/high-growth areas, and market drivers, which would help stakeholders devise and align their market strategies according to the current and future market dynamics.
The Europe Animal Model Market is anticipated to expand steadily, fueled by growing demand from pharmaceutical research, biomedical breakthroughs, and new drug development. Rodents, especially mice and rats, are widely employed in disease modeling, toxicology assessments, and basic research for evaluating safety and efficacy. Increased biotechnology funding and government-backed research programs are accelerating the adoption of animal models. The growing preference for genetically engineered and humanized models is strengthening preclinical studies, with pharmaceutical companies and academic institutes continuing to dominate as primary end-users.
Below mentioned are some prominent drivers and their influence on the market dynamics:
Driver |
Primary Segments Affected |
Why it matters (evidence) |
Rising R&D Investments |
Pharma & Biotech Companies |
Rising R&D investments by pharmaceutical companies are driving the need for dependable animal models to support drug discovery and preclinical safety assessments. |
Prevalence of Chronic Diseases |
All Segments |
Growing cases of cancer, diabetes, and cardiovascular diseases fuel the use of animal models for therapeutic research. |
Biotechnology Advancements |
Pharma, Academic Institutes |
Genetic engineering techniques have improved the relevance of animal models, driving their adoption in advanced research. |
Government-Funded Research Programs |
Academic Institutes, Pharma |
European governments are financing biomedical research, boosting reliance on animal models for preclinical testing. |
Regulatory Requirements for Preclinical Testing |
Pharma & Biotech Companies |
EU regulations strictly require that animal models be used for preclinical validation before advancing to clinical trial phases. |
Europe Animal Model Market is anticipated to witness significant expansion, registering a CAGR of 7.88% during the forecast period of 2025-2031.The Europe Animal Model Market Growth is driven by higher R&D expenditures by pharmaceutical and biotechnology companies and the rising incidence of chronic diseases, including cancer, diabetes, and cardiovascular disease. The increased importance of accurate preclinical drug validation has also driven the adoption of animal models in research. Advancements in biotechnology-towards genetically modified models and humanized models–added relevance and accuracy. In addition, government strategies supporting translational research will support wider adoption among academic institutes as well as the pharma and biotech community in Europe.
Below mentioned are some major restraints and their influence on the market dynamics:
Restraint |
Primary Segments Affected |
What this means (evidence) |
Ethical Concerns |
All Segments |
Ethical debates on animal testing and pressure from animal welfare organizations restrict widespread use. |
High Costs |
Pharma & Academic Institutes |
The use of advanced genetically modified models and specialized housing facilities raises operational expenses for research institutions. |
Alternative Testing Methods |
Pharma & Biotech Companies |
Growing use of in-vitro and computer-simulated models challenges the adoption of animal testing. |
Stringent EU Regulations |
All Segments |
The EU enforces strict ethical standards under Directive 2010/63/EU, which place clear limits on the use of animals in testing. |
Public Perception |
All Segments |
Growing public concern for animal welfare is reducing acceptance of animal testing and encouraging the shift toward alternative methods. |
The Europe Animal Model Industry encounters key challenges, with ethical debates on animal testing intensifying the move toward in-vitro alternatives. Maintaining genetically modified models and specialized housing raises operational costs, placing financial strain on institutions. EU directives on animal welfare add further compliance barriers. Furthermore, technological advances such as computer simulations and lab-on-a-chip systems threaten traditional usage. Maintaining a balance between advancing science and meeting ethical responsibilities remains a major obstacle for stakeholders in Europe.
Several prominent trends reshaping the market growth include:
Some prominent investment opportunities in the market include:
Some leading players operating in the Europe Animal Model Market Share include:
Company Name | Charles River Laboratories |
Established Year | 1947 |
Headquarters | Wilmington, Massachusetts, USA |
Official Website | Click Here |
Charles River is a global leader in providing preclinical laboratory services and animal models, supporting pharmaceutical and biotech drug discovery.
Company Name | Envigo RMS Holding Corp. |
Established Year | 1952 |
Headquarters | Indianapolis, USA |
Official Website | Click Here |
Envigo specializes in laboratory animal breeding and research services, providing essential models for biomedical and pharmaceutical studies.
Company Name | Taconic Biosciences |
Established Year | 1952 |
Headquarters | New York, USA |
Official Website | Click Here |
Taconic focuses on genetically engineered rodent models and microbiome solutions for drug discovery and translational research.
Company Name | Janvier Labs |
Established Year | 1960 |
Headquarters | Le Genest-Saint-Isle, France |
Official Website | Click Here |
Janvier Labs is a leading European provider of laboratory rodents and research services, emphasizing animal welfare and genetic expertise.
Company Name | Harvard Bioscience Inc. |
Established Year | 1901 |
Headquarters | Holliston, Massachusetts, USA |
Official Website | Click Here |
Harvard Bioscience delivers precision instruments and laboratory animal research solutions, supporting drug discovery and toxicology studies worldwide.
The European governments strictly regulate animal model research to balance science and ethics. The EU Directive 2010/63/EU ensures the humane and ethical use of animals in scientific studies. Germany enforces its Animal Welfare Act, requiring prior authorization for animal-based experiments. In the UK, the Animals (Scientific Procedures) Act 1986 emphasizes the 3Rs principle—Replacement, Reduction, and Refinement. France mandates ethical review boards for approvals while funding biomedical research. These frameworks collectively promote scientific progress while safeguarding animal welfare across Europe.
The Europe Animal Model Market is set for steady growth, driven by increasing demand for drug discovery, preclinical research, and biomedical innovation. Adoption of genetically engineered and humanized models is revolutionizing studies in oncology, neurology, and immunology, enhancing translational relevance. Strong collaborations between academia and industry, supported by EU biomedical initiatives, are boosting research capacity. Additionally, the integration of AI and advanced analytics with animal testing data is improving efficiency, making the sector more adaptable to evolving scientific requirements.
The report offers a comprehensive study of the subsequent market segments and their leading categories.
According to Ritika Kalra, Senior Research Analyst at 6Wresearch, Germany leads the market with the largest share, driven by strong pharmaceutical R&D infrastructure and government-backed biomedical funding. German academic institutions and pharma companies are extensively using animal models for oncology and neurological research. Strict regulatory oversight has not hindered progress but has encouraged innovation in genetically engineered and humanized models.
The mice segment holds the largest market share due to their genetic similarity to humans, short breeding cycles, and suitability for oncology and immunology research. Mice are widely used in genetic engineering experiments, making them indispensable in pharmaceutical drug development and academic studies across Europe.
Drug discovery and development is the leading application, driven by rising pharmaceutical R&D and clinical trial requirements. Companies rely on animal models to validate safety and efficacy before human testing. This segment dominates due to increasing demand for cancer research and therapeutic development.
Pharmaceutical and biotechnology companies account for the largest market share, given their extensive reliance on animal models for preclinical testing. Expanding investments in personalized medicine and biologics are further driving usage within this segment across Europe.
The report offers a comprehensive study of the subsequent market segments:
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Europe Animal Model Market Overview |
3.1 Europe Regional Macro Economic Indicators |
3.2 Europe Animal Model Market Revenues & Volume, 2021 & 2031F |
3.3 Europe Animal Model Market - Industry Life Cycle |
3.4 Europe Animal Model Market - Porter's Five Forces |
3.5 Europe Animal Model Market Revenues & Volume Share, By Countries, 2021 & 2031F |
3.6 Europe Animal Model Market Revenues & Volume Share, By Animal Type , 2021 & 2031F |
3.7 Europe Animal Model Market Revenues & Volume Share, By Application, 2021 & 2031F |
3.8 Europe Animal Model Market Revenues & Volume Share, By End Users, 2021 & 2031F |
4 Europe Animal Model Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.3 Market Restraints |
5 Europe Animal Model Market Trends |
6 Europe Animal Model Market, 2017 - 2031 |
6.1 Europe Animal Model Market, Revenues & Volume, By Animal Type , 2017 - 2031 |
6.2 Europe Animal Model Market, Revenues & Volume, By Application, 2017 - 2031 |
6.3 Europe Animal Model Market, Revenues & Volume, By End Users, 2017 - 2031 |
7 Germany Animal Model Market, 2017 - 2031 |
7.1 Germany Animal Model Market, Revenues & Volume, By Animal Type , 2017 - 2031 |
7.2 Germany Animal Model Market, Revenues & Volume, By Application, 2017 - 2031 |
7.3 Germany Animal Model Market, Revenues & Volume, By End Users, 2017 - 2031 |
8 United Kingdom Animal Model Market, 2017 - 2031 |
8.1 United Kingdom Animal Model Market, Revenues & Volume, By Animal Type , 2017 - 2031 |
8.2 United Kingdom Animal Model Market, Revenues & Volume, By Application, 2017 - 2031 |
8.3 United Kingdom Animal Model Market, Revenues & Volume, By End Users, 2017 - 2031 |
9 France Animal Model Market, 2017 - 2031 |
9.1 France Animal Model Market, Revenues & Volume, By Animal Type , 2017 - 2031 |
9.2 France Animal Model Market, Revenues & Volume, By Application, 2017 - 2031 |
9.3 France Animal Model Market, Revenues & Volume, By End Users, 2017 - 2031 |
10 Italy Animal Model Market, 2017 - 2031 |
10.1 Italy Animal Model Market, Revenues & Volume, By Animal Type , 2017 - 2031 |
10.2 Italy Animal Model Market, Revenues & Volume, By Application, 2017 - 2031 |
10.3 Italy Animal Model Market, Revenues & Volume, By End Users, 2017 - 2031 |
11 Russia Animal Model Market, 2017 - 2031 |
11.1 Russia Animal Model Market, Revenues & Volume, By Animal Type , 2017 - 2031 |
11.2 Russia Animal Model Market, Revenues & Volume, By Application, 2017 - 2031 |
11.3 Russia Animal Model Market, Revenues & Volume, By End Users, 2017 - 2031 |
12 Spain Animal Model Market, 2017 - 2031 |
12.1 Spain Animal Model Market, Revenues & Volume, By Animal Type , 2017 - 2031 |
12.2 Spain Animal Model Market, Revenues & Volume, By Application, 2017 - 2031 |
12.3 Spain Animal Model Market, Revenues & Volume, By End Users, 2017 - 2031 |
13 Rest of Europe Animal Model Market, 2017 - 2031 |
13.1 Rest of Europe Animal Model Market, Revenues & Volume, By Animal Type , 2017 - 2031 |
13.2 Rest of Europe Animal Model Market, Revenues & Volume, By Application, 2017 - 2031 |
13.3 Rest of Europe Animal Model Market, Revenues & Volume, By End Users, 2017 - 2031 |
14 Europe Animal Model Market Key Performance Indicators |
15 Europe Animal Model Market - Opportunity Assessment |
15.1 Europe Animal Model Market Opportunity Assessment, By Countries, 2021 & 2031F |
15.2 Europe Animal Model Market Opportunity Assessment, By Animal Type , 2021 & 2031F |
15.3 Europe Animal Model Market Opportunity Assessment, By Application, 2021 & 2031F |
15.4 Europe Animal Model Market Opportunity Assessment, By End Users, 2021 & 2031F |
16 Europe Animal Model Market - Competitive Landscape |
16.1 Europe Animal Model Market Revenue Share, By Companies, 2024 |
16.2 Europe Animal Model Market Competitive Benchmarking, By Operating and Technical Parameters |
17 Company Profiles |
18 Recommendations |
19 Disclaimer |